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Abstract
Context: Fructosamine is a glycemic biomarker which may be useful for indication and control of diabetes respectively.
Objective: The objective of the study was to evaluate fructosamine as an indicator of hyperglycaemia and glucose control in
subjects with diabetes.
Design, Setting & Patients: From the AMORIS cohort, subjects with serum glucose, fructosamine and HbA1c from the same
examination were studied cross-sectionally and longitudinally (n = 10,987; 5,590 overnight-fasting). The guidelines of the
American Diabetes Association were followed for classification of prediabetes and diabetes. Separate analyses were
performed in patients with a newly detected or a known diagnosis of type 1 or type 2 diabetes respectively.
Results: All three biomarkers were strongly correlated. With regard to the association between fructosamine and HbA1c
Pearson linear correlation coefficients in the range of 0.67–0.75 were observed in fasting and non-fasting subjects with type
1 or type 2 diabetes. Analyses of glucose control in fasting patients with type 2 diabetes having all three biomarkers
measured at three separate occasions within on average 290 days of the index examination showed similar trends over time
for glucose, fructosamine and HbA1c. Discrimination of subjects with and without diabetes across the range of fructosamine
levels was good (area under curve (AUC) 0.91–0.95) and a fructosamine level of 2.5 mmol/L classified subjects to diabetes
with a sensitivity of 61% and a specificity of 97%.
Conclusions: Fructosamine is closely associated with HbA1c and glucose respectively and may be a useful biomarker of
hyperglycaemia and glucose control in clinical and epidemiological studies.
Citation: Malmstro¨m H, Walldius G, Grill V, Jungner I, Gudbjo¨rnsdottir S, et al. (2014) Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in
Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS Cohort. PLoS ONE 9(10): e111463. doi:10.1371/journal.pone.
0111463
Editor: Marta L. Hribal, University of Catanzaro Magna Graecia, Italy
Received June 24, 2014; Accepted October 2, 2014; Published October 29, 2014
Copyright:  2014 Malmstro¨m et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. This study is based on
national registers in Sweden: the National Board of Health and Welfare, the National Cause-of-Death Register, and the National Patient Register. From Statistics
Sweden: the LISA database, Surveys of living conditions (ULF). The Swede-Heart Register, the National Diabetic Register (NDR) and several research registers;
WOLF, 60 years old men and women, COSM, SMC at Karolinska institutet (KI), Stockholm, Sweden. These datasets contain sensitive information. The database
used in the present paper is located in a security server at the institution (IMM, KI) with restricted access. This dataset is available upon request to the
corresponding author, given that the interested party can obtain approval from the data owners, the National Board of Health and Welfare in Sweden (http://
www.socialstyrelsen.se/english) and Statistics Sweden (http://www.scb.se/en_/) as well as from the owners of the research registers at KI, Stockholm, Sweden.
Funding: The study was funded by the Gunnar and Ingmar Jungner Foundation for Laboratory Medicine, Stockholm, Sweden. The funder had no role in study
design and analysis, decision to publish, or preparation of the manuscript but was responsible for the laboratory data Collection in 1985-1996 via the CALAB
laboratory.
Competing Interests: Niklas Hammar is an adjunct professor of epidemiology at the Institute of Environmental Medicine, Karolinska Institutet (KI) and also
employee of AstraZeneca Research & Development, Mo¨lndal, Sweden. The research of the current study has no relation to the drug development or other
activities performed by AstraZeneca and AstraZeneca had no influence on the initiation, conduct or interpretation of the study. The CALAB laboratory was
overtaken by another company in 1997 but the laboratory database containing data from 1985 to 1996 was still owned and managed by Ingmar Jungner.
Jungner donated the database to the Institute of Environmental Medicine in 2012. Ingmar Jungner is retired since many years and is not active in any business
activities. He still is a member of the AMORIS Steering Committee. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
* Email: Hakan.Malmstrom@ki.se
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e111463
Introduction
Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are
established indicators of glucose status and its control. Definitions
from different health organizations use FPG or HbA1c cut-offs of
$7 mmol/L and $6.5% (48 mmol/mol) respectively either as
single indicators or combined to diagnose diabetes [1–5]. HbA1c
reflects the glucose concentration during the entire lifespan of the
red blood cells but to the largest extent the 6–8 weeks preceding
the time of measurement [6]. Certain factors, e.g. red blood cell
disorders, could potentially bias the measurement of HbA1c and
therefore alternative markers could be useful [6]. One such marker
is fructosamine which relates to average levels of glucose during
the preceding 1 to 3 weeks [6], [7]. Fructosamine may give an
earlier indication of poorly controlled glucose compared to HbA1c.
It is a simple, robust and inexpensive biomarker that could
potentially be a useful tool in large epidemiological and clinical
studies either as a standalone indicator of hyperglycaemia or in
combination with glucose and HbA1c [8]. Importantly, fructosa-
mine may be reliably measured irrespective of fasting or non-
fasting. However, fructosamine is rarely used in clinical practice
and has not been extensively evaluated as an indicator of diabetes
and its micro-and macro vascular complications in large popula-
tion based studies. Various cut-offs for fructosamine as well as
correlations to glucose and HbA1c have been published based on
rather small cohorts of patients [9–14]. Recently, fructosamine has
been showed to be an independent biomarker to predict incident
diabetes and its microvascular complications [15].
The aim of the present study was to explore the relationship
between serum glucose, serum fructosamine and HbA1c cross-
sectionally and over time in a large population with a wide
variation in glucose and HbA1c values. An additional aim was to
investigate the sensitivity and specificity of various fructosamine
cut-offs in identification of subjects with prediabetes and diabetes
using established diagnostic criteria based on HbA1c and FPG.
Materials and Methods
The study was based on the AMORIS cohort that has been
described in detail previously [16], [17]. This cohort was recruited
during 1985–1996 mainly from the greater Stockholm area. The
cohort subjects were healthy and referred for clinical laboratory
testing as part of a health check-up or were outpatients referred for
laboratory testing. No samples were from inpatients. The
AMORIS population consists of 812,073 subjects of all ages with
varying information on a number of biomedical factors. Subjects
were frequently followed with repeated examinations. For a total
of 10,987 individuals, 5,199 males and 5,788 females, there was
complete in-formation on serum glucose, serum fructosamine and
HbA1c from the same ex-amination. Of these individuals, 5,590
were known to be overnight-fasting at the time of the index
examination which was defined as the first time glucose,
fructosamine and HbA1c were measured at the same occasion.
For a repeated measurement analysis we identified type 2 diabetes
patients (n = 254) with assessments of all biomarkers at the index
examination as well as within 0–6 months and 6–12 months. In
the case of multiple assessments within one of these time windows,
we used the assessment farthest from the index examination.
Subjects were grouped on whether they had increased or reduced
glucose levels at the third examination.
Laboratory methods
All laboratory examinations were performed at the CALAB
laboratory (CALAB laboratories, Stockholm, Sweden), a labora-
tory accredited by SWEDAC (Swedish Board for Technical
Accreditation). Serum glucose was measured enzymatically with a
glucose oxidase/peroxidase method based on an enzymatic
colorimetric technique according to the GOD-PAP method with
automated multichannel analyzers (AutoChemist-PRISMA
(PRISMA) and Technicon DAX 96). Total imprecision was
CV,3%. Values of serum glucose are virtually identical to plasma
glucose only differing by about 1% [18]. In the AMORIS study
serum glucose values were standardized versus international
standards of plasma glucose.
Fructosamine was measured by the Nitroblue Teterazolium
(NBT) colorimetric technique devised by Johnson [19] based on
the reducing ability of fructosamine in an alkaline solution and
performed with the same automated analyzers as for serum
glucose. Total imprecision was CV,5%.
Two methods were used to determine HbA1c. From 1992 and
until the end of 1994 the method was based on affinity binding
and quantitative determination of glycated hemoglobin in
anticoagulated whole blood [20], [21] and performed with the
Abbot Vision System. The results were adjusted to be HbA1c and
calibrated to DCCT values. Total CV was 4.4% at level
4.8 mmol/L and 2.8% at level 8.9 mmol/L. Reagents and three
levels of calibrators from Abbott Diagnostics (Lake Forest, Illinois,
USA) were used. The second method used since 1995 was based
on a two-channel method, UNIMATE [22], automated on the
analyzer Hitachi 917, for the immunological/colorimetric deter-
mination of % HbA1c. Here HbA1c was measured by latex
enhanced turbidimetry [23] and total Hb colorimetrically [24].
Total CV was ,4.5%.
Albumin was colorimetrically measured based on its binding
with bromocresol green. The CV was #2.0% at level 35 and
46 g/L and#2.5% at level 26 g/L. The concentration of albumin
could potentially influence the concentration of fructosamine [7].
Hence, when possible we also calculated albumin corrected
fructosamine using the following formula: (fructosamine (mmol/
L)/albumin (g/L) x100) [25]. Glomerular filtration rate (eGFR)
was estimated by the Epidemiology Collaboration (CKD-EPI)
formula [26]. Classification of chronic kidney disease was defined
as an eGFR less than 60 mL/min per 1.73 m2.
Classification of glucose tolerance
We used the plasma glucose levels and HbA1c values as defined
by the American Diabetes Association (ADA) guidelines [1], [2]
for the diagnosis of type 2 diabetes. Subjects were classified into
five groups: normal glucose tolerance, prediabetes, newly diag-
nosed type 2 diabetes (NewT2D), previously diagnosed type 2
diabetes (DiagnosedT2D) and type 1 diabetes (T1D). This
classification was based on glucose level at the index examination
or by information of type 1 or type 2 diabetes prior to index
examination based on other sources. Following the guidelines of
ADA, we classified fasting serum glucose (FSG) below 5.6 mmol/L
or HbA1c below 5.7% (39 mmol/mol) as normal glucose
tolerance. FSG of 5.6–6.9 mmol/L or HbA1c between 5.7% and
6.4% (39–46 mmol/mol) was classified as prediabetes. FSG above
6.9 mmol/L or HbA1c of 6.5% (48 mmol/mol) and above was
classified as type 2 diabetes (NewT2D). In addition, if a subject
had a random glucose of 11.1 mmol/L or above this was
considered as NewT2D. Subjects who had information about
hospitalization with diabetes as discharge diagnosis prior to the
index examination were classified according to the discharge
diagnosis (DiagnosedT2D). Subjects registered in the Swedish
National Diabetes Register (NDR) were classified as type 1 (T1D)
or type 2 diabetes (DiagnosedT2D) according to the diagnostic
criteria set out in the register. As regards NDR, if no specific type
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was defined the clinical diagnosis by the referring physician was
used. When registered as unspecified diabetes in the NDR or
detected by the glucose criterion in AMORIS we classified subjects
less than 30 years of age as T1D. Subjects diagnosed by the
Swedish medical birth register (MFR) with gestational diabetes
within one year prior or one year after the index examination were
excluded from this study.
Patient characteristics
Socioeconomic factors were obtained from several databases
maintained by the Statistics Sweden. Those databases were
the1990 national education database, the 1990 national census
for occupation and the multi-generation register to obtain country
of birth. Information on medical history including cardi-ovascular
events, overall anemia, nephrosis and cancer prior to the index
examination were obtained from inpatient registers and the cancer
register maintained by the Swedish National Board of Health and
Welfare. BMI was collected from the AMORIS laboratory
database when assessed at any examination or from the NDR,
national survey of living conditions (ULF, Statistics Sweden), the
medical birth register (MFR, National Board of Health and
Welfare), the Swedish Twin Registry or quality of care registers
included in SWEDEHEART (Uppsala Clinical Research Center,
UCR). The BMI closest to the date of the index examination was
used for adjustment of the associations. Data on BMI were
available in about 40% of subjects. Serum albumin, creatinine,
lipoproteins and apolipoproteins were obtained from the index
examination. Triglycerides, total cholesterol, albumin and creat-
inine were available for about 90% and high and- low density
lipoprotein cholesterol (HDL-C, LDL-C) as well as apolipopro-
teins A-1 and B (ApoA-1, ApoB) for about 50% of the subjects.
Ethical statement
This study is part of a project entitled ‘‘Metabolic abnormalities
and inflammation in relation to chronic disease primarily
cardiovascular diseases, kidney disease, cancer, dementia, rheu-
matoid arthritis and psychiatric illness – epidemiological studies
based on the AMORIS population’’.
This project has been approved by the Regional Ethical
committee at Karolinska Institutet, Stockholm, Sweden (Registra-
tion number 2010/1:7). All the study data was de-identified and
the Ethical committee approved the project without collecting any
additional informed consent.
Statistical Analysis
All analyses were performed using SAS software (SAS Institute
Inc., Cary, NC, USA). Pearson’s correlation coefficients and
partial correlations were calculated using the SAS correlation
procedure. A change in the point estimate of 10% or more was
used as criteria for inclusion of a covariate in the multivariable
models for confounding adjustment purposes. Sensitivity and
specificity to classify diabetes were calculated using binary tables at
various levels of fructosamine and with ADA criteria as the
reference standard. Receiving operator characteristic analyses
(ROC) were performed and area under the curve (AUC) with 95%
Wald confidence limits estimated according to Mann-Whitney
with PROC LOGISTIC. Series of the arithmetic mean values for
glucose and HbA1c per percentile of fructosamine were graphically
displayed with corresponding 1 SD range using PROC MEANS
and PROC SGPLOT. For the repeated measurement analyses,
arithmetic mean values by biomarker and time window were
calculated and graphically presented.
Results
Characteristics of subjects
Subject characteristics are presented in Table 1. There were
5,714 subjects (51% of all) who were cat-egorized as having
normal glucose tolerance, 1,877 with prediabetes (17%) and 3,116
with type 2 diabetes (29%). Of the subjects classified as type 2
diabetes, 1,256 were diagnosed at the index examination i.e.
NewT2D and 1,860 had a known diagnosis of type 2 diabetes. A
total of 280 patients were diagnosed with type 1 diabetes. Fasting
subjects in the NewT2D group (n= 759) were detected by a
glucose value of 7 mmol/l or above in 94% of the subjects.
Simultaneously, 51% of those subjects also had HbA1c above
6.5%. The gender distribution was balanced, 47% males and 53%
females, although females were relatively fewer among subjects
with type 2 diabetes.
The mean age in the study population was 57 years with a range
from 2 to 97 years. The subjects with normal glucose tolerance
were somewhat younger than subjects with T2D. Those with
DiagnosedT2D had more often a history of cardiovascular disease
compared to the group with normal glucose tolerance. A history of
cancer was similar across the categories. The NewT2D group had
similar clinical characteristics compared to the DiagnosedT2D
group except for a lower frequency of history of cardiovascular
diseases. Mean values of triglycerides, total cholesterol, ApoB and
the ApoB/ApoA-I ratio increased and mean values of HDL-C and
ApoA-I successively decreased from subjects with normal glucose
levels to those with pre-diabetes and newly diagnosed type 2
diabetes.
Diabetes-induced increases of markers of glycaemia
In the fasting state, fructosamine increased from an average of
2.03 mmol/L in subjects with normal glucose tolerance to
2.11 mmol/L in the prediabetes group and to 2.62 mmol/L in
the NewT2D group. Similarly to fructosamine, HbA1c increased
from an average of 4.76% (29 mmol/mol) to 5.14% (33 mmol/
mol) in the prediabetes group and to 6.93% (52 mmol/mol) in the
NewT2D group. Neither for fructosamine nor HbA1c did
DiagnosedT2D markedly diverge from NewT2D. Concentrations
were markedly higher for the T1D group compared to the groups
with type 2 diabetes (2.93 mmol/L for fructosamine and 7.62%
for HbA1c).
Associations between various glucose markers
Across glucose levels, strong associations were found for
fructosamine with glucose and HbA1c respectively, r = 0.75 and
r = 0.78 respectively in the entire cohort (Figure 1). Fructosamine
correlated with similar strength to HbA1c, r = 0.79 and glucose,
r = 0.80 in the fasting state. The linear correlations for fructosa-
mine and HbA1c was identical, r = 0.75, in the NewT2D and
DiagnosedT2D group respectively (Figure 2). Corresponding
linear correlations for non-fasting subjects were r = 0.69 and
r = 0.72. Subjects with T1D showed a similar association between
fructosamine and HbA1c as the subjects with DiagnosedT2D or
NewT2D. The linear correlation was r = 0.67 in fasting subjects
with T1D. Much lower correlations were found in the prediabetes
group, r = 0.11 and r = 0.17, in the fasting and non-fasting subjects
respectively and no clear association in subjects with normal
glucose tolerance. Adjusting for gender, age, albumin, BMI, total
cholesterol and triglycerides, affected associations only marginally.
Exclusion of subjects with previously diagnosed anemia, chronic
kidney insufficiency or diagnosed nephrosis respectively did not
alter the associations.
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Fructosamine, HbA1c and glucose in repeated
measurements
Figure 3 shows the results for fasting subjects with type 2
diabetes (n = 254) in whom three repeated measurements of
glucose, fructosamine and HbA1c were available. In the NewT2D
group glucose levels had increased on average by 27% after a
mean of 290 days. Simultaneously fructosamine and HbA1c
increased by 4.6% and 3.3%, respectively. Corresponding results
for DiagnosedT2D subjects were a 29% increase in glucose, a
6.8% increase in fructosamine and a 7.1% increase in HbA1c. In
subjects with NewT2D who manifested a decrease of mean
Figure 1. Overall associations of S-Fructosamine with S-Glucose and B-HbA1c respectively. All fasting states and all levels of glycemia
included (All subjects).
doi:10.1371/journal.pone.0111463.g001
Figure 2. Correlations of S-Fructosamine and B-HbA1c by fasting status, type 2 diabetes (new and diagnosed) and type 1 diabetes.
Fitted regression line with 95% confidence and prediction limits. Reference lines at fructosamine 2.5 mmol/L and at HbA1c 6.5% (48 mmol/mol).
doi:10.1371/journal.pone.0111463.g002
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glucose level by 18% after a mean of 290 days, the mean decrease
of fructosamine was 7.4% and that of HbA1c 6.6%. Corresponding
results for the DiagnosedT2D group were for glucose 22%,
fructosamine 10.2% and HbA1c 11.9%. Thus, there were parallel
changes over time in the evolution of glucose, fructosamine and
HbA1c in those who increased, and those who decreased their
glucose level. Figure 4 shows individual changes in the biomarkers
over time. The correlation coefficients for the changes were similar
regardless of time point for follow-up.
Hyperglycemia (diabetes) based on fructosamine
compared with ADA diagnostic criteria
Mean values were calculated for HbA1c and glucose respectively
among the fasting subjects by percentiles of fructosamine
(Figure 5). At a level of fructosamine of 2.5 mmol/L, the mean
values of both glucose and HbA1c were diagnostic for diabetes by
ADA criteria. When ADA criteria for classification of diabetes, i.e.
FSG$7 mmol/L or an HbA1c$6.5% (48 mmol/mol) was used a
fructosamine cut-off of 2.5 mmol/L correctly diagnosed 61% as
diabetes and correctly rejected 97% of the non-diabetes individ-
uals. Corresponding sensitivity and specificity for non-fasting
subjects were 82% and 94% respectively. The area under the
ROC curve (AUC) for diagnosing diabetes by fructosamine when
the ADA criteria were used to define diabetes was AUC=0.91 in
the fasting and AUC=0.95 in the non-fasting state, a finding
which indicated good discrimination across levels of fructosamine.
By separately modelling HbA1c and fructosamine respectively to
explain diabetes defined solely based on glucose criterion, the
AUCs were similar for the two biomarkers fructosamine and
HbA1c, 0.91 and 0.90 respectively. The AUC obtained by defining
diabetes by fructosamine when both glucose and HbA1c criteria
were met was AUC=0.96.The fructosamine cut-off 2.5 mmol/L
was applied in analyses of all fasting subjects in the AMORIS
cohort, n,255,000, using solely the glucose $7 mmol/L as
criterion. The results showed identical sensitivity and somewhat
higher specificity (61% and 98%) compared with the current study
population (results not shown).
Discussion
The present results are based on a large population represen-
tative for the working general population of Stockholm at the time
of laboratory examinations. We found close associations between
fructosamine, glucose and HbA1c, overall and particularly in
subjects with either type 1 or type 2 diabetes. These findings are
consistent with earlier but smaller studies [9–13] and also with
recently published results from the ARIC study where an overall
correlation of r = 0.82 was found [15]. Importantly, we found
similar relations between fructosamine and HbA1c irrespective of
fasting or non-fasting. The inter-relationship between fructosa-
mine and HbA1c as well as association with glucose levels in those
Figure 3. Mean values of S-Fructosamine, S-Glucose and B-HbA1c over time by increase/reduction of S-Glucose at on average 290
days after the index examination. Fasting subjects with new or diagnosed type 2 diabetes and with three simultaneous measurements of the
biomarkers within one year are included.
doi:10.1371/journal.pone.0111463.g003
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with prediabetes was less striking and was not seen in those with
normal glucose values. Hence, the relationship between fructosa-
mine and HbA1c to fasting glucose levels respectively indicates a
curvilinear relationship as has also previously been pointed out [7],
[12]. Importantly, our results from AMORIS were obtained in a
much larger population of men and women in all ages and with a
much wider range of glucose (up to 40 mmol/L), fructosamine (up
to 7.5 mmol/L) and HbA1c (up to 16.5%), than in studies
published previously [9–14]. Subjects with prediabetes and
especially manifest diabetes were characterized by features
common in subjects with metabolic syndrome and manifest
diabetes such as high BMI, hypertriglyceridemia, low HDL
cholesterol high apoB and low apoA-I giving the typical
manifestations of high atherogenic apoB/apoA-I ratios as
reviewed [27]. However, the relations between glucose, fructosa-
mine and HbA1c remained basically unchanged when controlling
for age, gender, BMI or lipid levels. In addition, albumin
correction of the fructosamine may only improve precision to a
small degree regarding monitoring of variability of glucose values.
Hence, the cross-sectional association of fructosamine with
different degrees of hyperglycaemia appears robust.
Previously, Baker et al. showed strong association between
fructosamine and HbA1c in the interval r = 0.70 to r = 0.87 in
patients with type 2 diabetes [9–11]. A more recent study by
Cohen et al. included 153 subjects with varied types of diabetes
[13]. They observed a correlation of r = 0.78. Juraschek et al. also
reported a similar linear correlation but also suggested polynomial
models as the best fit [12]. All of the above studies had rather small
study populations with limited number of subjects with high
glucose levels. Thus, the present AMORIS study confirmed the
correlations from earlier work but in a much larger study
population.
Moreover, Juraschek et al. evaluated various criteria for
diabetes by presenting AUC measures. They reported an AUC
of 0.83 for both fructosamine and fasting glucose if diabetes was
defined by an HbA1c of 6.5% (48 mmol/L) [12]. The diagnostic
discrimination by using fructosamine in the AMORIS study,
which is based on a much larger population, was higher, up to
AUC=0.95.
When subgroups of individuals in which glucose, fructosamine
and HbA1c were measured simultaneously up to 6 and 12 months
(on average 120 and 290 days respectively), fructosamine and
HbA1c changed in parallel both in those who increased their
glucose values and in those whose glucose values were consider-
ably reduced (possibly due to better adherence to dietary and/or
pharmacological therapy). Although individual discordant differ-
ences in directions were observed the major part of those was in
individuals with minor changes of hyperglycaemia which likely
would be more sensitive to random variation. Thus, these data
indicate that fructosamine can be used to monitor glucose control
over time in a similar way as HbA1c.
Figure 4. Individual changes and correlations of S-Fructosamine, S-Glucose and B-HbA1c over time. Fasting subjects with new or
diagnosed type 2 diabetes and with three simultaneous measurements of the biomarkers within one year are included.
doi:10.1371/journal.pone.0111463.g004
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The results of the present study indicate that fructosamine
discriminates well between subjects with and without diabetes
across all levels of the biomarker with an AUC over 90%. For
specific levels of fructosamine it is also possible to identify subjects
with type 2 diabetes with a reasonable sensitivity and a high
specificity. Our results would suggest a fructosamine somewhere in
the range of 2.3–2.6 for this purpose. Recently, Selvin et al showed
an adjusted hazard ratio for incident diabetes of 4.96 for those
above 2.64 mmol/L compared to those below 2.41 mmol/L [15].
These levels are in line with those of our study. Notably, in follow-
up studies of the outcome in diabetes patients a non-differential
misclassification of exposure (in this case type 2 diabetes) in terms
of reduced sensitivity does not influence estimates of relative risks.
A reduced specificity would tend to bias relative risk estimates
towards the null. For estimates of prevalence rates, and in
particular in a clinical setting, the effects of a reduced sensitivity
and specificity could be misleading or unacceptable. In our
estimates of sensitivity and specificity we used diagnostic criteria
based on fasting serum glucose and HbA1c according to ADA
guidelines. It cannot be ruled out that this ‘gold standard’ also
misclassified some subjects. Thus, the interpretation of our findings
should be made with the awareness of a certain degree of
misclassification of the disease in all definitions based on the
different biomarkers. The results of this study indicate that
fructosamine does very well in the comparison to the established
diagnostic biomarkers both in the identification of subjects with
hyperglycaemia or diabetes and in the evaluation of long term
glucose control in subjects with manifest diabetes. It would be of
greatest importance to examine the prognostic association between
fructosamine and major outcomes including cardiovascular disease
and hence subsequent studies from the AMORIS cohort will have
that focus.
Strengths
Strengths of this study include the fact that a single laboratory
was used for determination of all biomarkers (CALAB laborato-
ries, Stockholm, Sweden), that all analyses were performed on
fresh blood samples, that all methods are well documented and
that they are rigorously standardized. It is therefore unlikely that
the relations between these three markers of glucose metabolism
are biased due to poorly controlled methods or erroneous
classification or due to the variation of nutritional status and
potential confounders in this large population. Further, the study’s
size with 5,590 subjects known to be fasting whereof 3,063 with
impaired or abnormal glucose levels, to our knowledge is the
largest used for this purpose. Moreover it is a rather homogenous
population with 80% known to be born in Sweden and additional
5% in Finland. The large AMORIS population of 812,073 men
and women is representative of the larger Stockholm population as
previously documented [28]. The sub-cohort studied in this paper
is also representative for the whole AMORIS study population
regarding education and country of birth but with a somewhat
lower proportion of blue-collar workers.
Limitations
The study population was required to have glucose, fructosa-
mine and HbA1c measured at the same time. It is likely that the
individuals included in the study visited general physicians for
evaluation of a possible diabetes diagnosis or for diabetes control.
This could explain the fact that the proportion of subjects with
type 2 diabetes in this study was much higher than in the general
population. It is also of note that the proportion of individuals who
had a history of cardiovascular diseases and cancer was higher in
the study population compared with the whole AMORIS cohort.
We used a randomly measured glucose value of 11.1 mmol/L
or above as a diagnosis of diabetes in non-fasting subjects.
Figure 5. Mean values of fasting serum glucose and HbA1c by percentiles of S-Fructosamine with corresponding 1 standard
deviation. Sensitivity/Specificity at various fructosamine cut-off values for diagnosis of diabetes according to ADA criteria, 2.3 mmol/L (79%, 88%),
2.5 mmol/L (61%, 97%), 2.6 mmol/L (52%, 99%). Diagnostic discrimination of diabetes by S-Fructosamine using ROC analysis: AUC= 0.91 (fasting)
AUC= 0.95 (non-fasting).
doi:10.1371/journal.pone.0111463.g005
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Although not strictly adherent to ADA criteria (to be used only for
symptomatic hyperglycaemia), the small number diagnosed solely
by this criterion in this study, n= 14, most likely did not affect the
results. In addition, the AMORIS population consists largely of
subjects born in Sweden or in other Northern European countries.
With regard to age there is a broad representation including also
many subjects less than 30 years of age.
In conclusion, fructosamine is closely associated with HbA1c
and glucose particularly in patients with type 1 or type 2 diabetes.
Fructosamine and HbA1c tend to parallel each other over time in
subjects with diabetes indicating similar reflections of glucose
control. The results also suggest that fructosamine discriminates
well between subjects with and without diabetes. Fructosamine
may be a useful biomarker of hyperglycaemia in epidemiological
and clinical studies. Future outcome studies may investigate
relationships between levels of fructosamine and risks to develop
myocardial infarction, stroke and diabetic complications.
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